Skip to main content
Erschienen in: Journal of Neural Transmission 2/2012

01.02.2012 | Basic Neurosciences, Genetics and Immunology - Original Article

Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice

verfasst von: Sara K. Olsson, Markus K. Larsson, Sophie Erhardt

Erschienen in: Journal of Neural Transmission | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

The neuromodulating tryptophan metabolite kynurenic acid (KYNA) is increased in the brain of patients with schizophrenia. In the present study we investigate the spontaneous locomotor activity as well as the locomotor response to d-amphetamine [5 mg/kg, administered intraperitoneal (i.p.)] after increasing endogenous levels of brain KYNA in mice by acute (10 mg/kg, i.p., 60 min) or subchronic (100 mg/kg i.p., twice daily for 6 days) pretreatment with the blood–brain crossing precursor, l-kynurenine. We found that an acute increase in the brain KYNA levels caused increased corner time and percent peripheral activity but did not change the d-amphetamine-induced locomotor response. In contrast, subchronic elevation of KYNA did not change the spontaneous locomotor activity but produced an exaggerated d-amphetamine-induced hyperlocomotion. These results cohere with clinical studies of patients with schizophrenia, where a potentiated DA release associated with exacerbation of positive symptoms has been observed following d-amphetamine administration. Present results further underscore KYNA as a possible mediator of the aberrant dopaminergic neurotransmission seen in schizophrenia.
Literatur
Zurück zum Zitat Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155(6):761–767PubMed Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155(6):761–767PubMed
Zurück zum Zitat Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, Breier A (1999) Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 156(10):1646–1649PubMed Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, Breier A (1999) Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 156(10):1646–1649PubMed
Zurück zum Zitat Allen RM, Young SJ (1978) Phencyclidine-induced psychosis. Am J Psychiatry 135(9):1081–1084PubMed Allen RM, Young SJ (1978) Phencyclidine-induced psychosis. Am J Psychiatry 135(9):1081–1084PubMed
Zurück zum Zitat Amori L, Guidetti P, Pellicciari R, Kajii Y, Schwarcz R (2009) On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J Neurochem 109(2):316–325PubMedCrossRef Amori L, Guidetti P, Pellicciari R, Kajii Y, Schwarcz R (2009) On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J Neurochem 109(2):316–325PubMedCrossRef
Zurück zum Zitat Anand R, Peng X, Ballesta JJ, Lindstrom J (1993) Pharmacological characterization of alpha-bungarotoxin-sensitive acetylcholine receptors immunoisolated from chick retina: contrasting properties of alpha 7 and alpha 8 subunit-containing subtypes. Mol Pharmacol 44(5):1046–1050PubMed Anand R, Peng X, Ballesta JJ, Lindstrom J (1993) Pharmacological characterization of alpha-bungarotoxin-sensitive acetylcholine receptors immunoisolated from chick retina: contrasting properties of alpha 7 and alpha 8 subunit-containing subtypes. Mol Pharmacol 44(5):1046–1050PubMed
Zurück zum Zitat Bender DA, McCreanor GM (1982) The preferred route of kynurenine metabolism in the rat. Biochim Biophys Acta 717(1):56–60PubMedCrossRef Bender DA, McCreanor GM (1982) The preferred route of kynurenine metabolism in the rat. Biochim Biophys Acta 717(1):56–60PubMedCrossRef
Zurück zum Zitat Beninger RJ, Beuk J, Banasikowski TJ, van Adel M, Boivin GA, Reynolds JN (2010) Subchronic phencyclidine in rats: alterations in locomotor activity, maze performance, and GABA (A) receptor binding. Behav Pharmacol 21(1):1–10PubMedCrossRef Beninger RJ, Beuk J, Banasikowski TJ, van Adel M, Boivin GA, Reynolds JN (2010) Subchronic phencyclidine in rats: alterations in locomotor activity, maze performance, and GABA (A) receptor binding. Behav Pharmacol 21(1):1–10PubMedCrossRef
Zurück zum Zitat Birch PJ, Grossman CJ, Hayes AG (1988) Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol 154(1):85–87PubMedCrossRef Birch PJ, Grossman CJ, Hayes AG (1988) Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol 154(1):85–87PubMedCrossRef
Zurück zum Zitat Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94(6):2569–2574PubMedCrossRef Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94(6):2569–2574PubMedCrossRef
Zurück zum Zitat Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, Malhotra AK, Pickar D (1998) Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29(2):142–147PubMedCrossRef Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, Malhotra AK, Pickar D (1998) Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29(2):142–147PubMedCrossRef
Zurück zum Zitat Carpenedo R, Pittaluga A, Cozzi A, Attucci S, Galli A, Raiteri M, Moroni F (2001) Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur J Neurosci 13(11):2141–2147PubMedCrossRef Carpenedo R, Pittaluga A, Cozzi A, Attucci S, Galli A, Raiteri M, Moroni F (2001) Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur J Neurosci 13(11):2141–2147PubMedCrossRef
Zurück zum Zitat Chess AC, Bucci DJ (2006) Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behav Brain Res 170(2):326–332PubMedCrossRef Chess AC, Bucci DJ (2006) Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behav Brain Res 170(2):326–332PubMedCrossRef
Zurück zum Zitat Chess AC, Simoni MK, Alling TE, Bucci DJ (2007) Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 33(3):797–804PubMedCrossRef Chess AC, Simoni MK, Alling TE, Bucci DJ (2007) Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 33(3):797–804PubMedCrossRef
Zurück zum Zitat Chess AC, Landers AM, Bucci DJ (2009) l-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning. Behav Brain Res 201(2):325–331PubMedCrossRef Chess AC, Landers AM, Bucci DJ (2009) l-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning. Behav Brain Res 201(2):325–331PubMedCrossRef
Zurück zum Zitat Connor TJ, Starr N, O’Sullivan JB, Harkin A (2008) Induction of indolamine 2, 3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma? Neurosci Lett 441(1):29–34PubMedCrossRef Connor TJ, Starr N, O’Sullivan JB, Harkin A (2008) Induction of indolamine 2, 3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma? Neurosci Lett 441(1):29–34PubMedCrossRef
Zurück zum Zitat Coyle JT (2006) Glial metabolites of tryptophan and excitotoxicity: coming unglued. Exp Neurol 197(1):4–7PubMedCrossRef Coyle JT (2006) Glial metabolites of tryptophan and excitotoxicity: coming unglued. Exp Neurol 197(1):4–7PubMedCrossRef
Zurück zum Zitat Erhardt S, Engberg G (2002) Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiol Scand 175(1):45–53PubMedCrossRef Erhardt S, Engberg G (2002) Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiol Scand 175(1):45–53PubMedCrossRef
Zurück zum Zitat Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G (2001a) Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 313(1–2):96–98PubMedCrossRef Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G (2001a) Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 313(1–2):96–98PubMedCrossRef
Zurück zum Zitat Erhardt S, Oberg H, Mathe JM, Engberg G (2001b) Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids 20(4):353–362PubMedCrossRef Erhardt S, Oberg H, Mathe JM, Engberg G (2001b) Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids 20(4):353–362PubMedCrossRef
Zurück zum Zitat Erhardt S, Schwieler L, Emanuelsson C, Geyer M (2004) Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry 56(4):255–260PubMedCrossRef Erhardt S, Schwieler L, Emanuelsson C, Geyer M (2004) Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry 56(4):255–260PubMedCrossRef
Zurück zum Zitat Foster AC, White RJ, Schwarcz R (1986) Synthesis of quinolinic acid by 3-hydroxyanthranilic acid oxygenase in rat brain tissue in vitro. J Neurochem 47(1):23–30PubMedCrossRef Foster AC, White RJ, Schwarcz R (1986) Synthesis of quinolinic acid by 3-hydroxyanthranilic acid oxygenase in rat brain tissue in vitro. J Neurochem 47(1):23–30PubMedCrossRef
Zurück zum Zitat French ED (1994) Phencyclidine and the midbrain dopamine system: electrophysiology and behavior. Neurotoxicol Teratol 16(4):355–362PubMedCrossRef French ED (1994) Phencyclidine and the midbrain dopamine system: electrophysiology and behavior. Neurotoxicol Teratol 16(4):355–362PubMedCrossRef
Zurück zum Zitat French ED, Mura A, Wang T (1993) MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists. Synapse 13(2):108–116PubMedCrossRef French ED, Mura A, Wang T (1993) MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists. Synapse 13(2):108–116PubMedCrossRef
Zurück zum Zitat Gal EM, Sherman AD (1978) Synthesis and metabolism of l-kynurenine in rat brain. J Neurochem 30(3):607–613PubMedCrossRef Gal EM, Sherman AD (1978) Synthesis and metabolism of l-kynurenine in rat brain. J Neurochem 30(3):607–613PubMedCrossRef
Zurück zum Zitat Ganong AH, Cotman CW (1986) Kynurenic acid and quinolinic acid act at N-methyl-d-aspartate receptors in the rat hippocampus. J Pharmacol Exp Ther 236(1):293–299PubMed Ganong AH, Cotman CW (1986) Kynurenic acid and quinolinic acid act at N-methyl-d-aspartate receptors in the rat hippocampus. J Pharmacol Exp Ther 236(1):293–299PubMed
Zurück zum Zitat Guidetti P, Eastman CL, Schwarcz R (1995) Metabolism of [5–3H] kynurenine in the rat brain in vivo: evidence for the existence of a functional kynurenine pathway. J Neurochem 65(6):2621–2632PubMedCrossRef Guidetti P, Eastman CL, Schwarcz R (1995) Metabolism of [5–3H] kynurenine in the rat brain in vivo: evidence for the existence of a functional kynurenine pathway. J Neurochem 65(6):2621–2632PubMedCrossRef
Zurück zum Zitat Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21(19):7463–7473PubMed Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21(19):7463–7473PubMed
Zurück zum Zitat Jentsch JD, Taylor JR, Roth RH (1998) Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 19(2):105–113PubMedCrossRef Jentsch JD, Taylor JR, Roth RH (1998) Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 19(2):105–113PubMedCrossRef
Zurück zum Zitat Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M (2000) Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 48(7):627–640PubMedCrossRef Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M (2000) Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 48(7):627–640PubMedCrossRef
Zurück zum Zitat Kessler M, Terramani T, Lynch G, Baudry M (1989) A glycine site associated with N-methyl-d-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52(4):1319–1328PubMedCrossRef Kessler M, Terramani T, Lynch G, Baudry M (1989) A glycine site associated with N-methyl-d-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52(4):1319–1328PubMedCrossRef
Zurück zum Zitat Kita T, Morrison PF, Heyes MP, Markey SP (2002) Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the l-kynurenine and quinolinic acid pools in brain. J Neurochem 82(2):258–268PubMedCrossRef Kita T, Morrison PF, Heyes MP, Markey SP (2002) Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the l-kynurenine and quinolinic acid pools in brain. J Neurochem 82(2):258–268PubMedCrossRef
Zurück zum Zitat Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D’Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93(17):9235–9240PubMedCrossRef Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D’Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93(17):9235–9240PubMedCrossRef
Zurück zum Zitat Linderholm KR, Andersson A, Olsson S, Olsson E, Snodgrass R, Engberg G, Erhardt S (2007) Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis. Neuropharmacology 53(8):918–924PubMedCrossRef Linderholm KR, Andersson A, Olsson S, Olsson E, Snodgrass R, Engberg G, Erhardt S (2007) Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis. Neuropharmacology 53(8):918–924PubMedCrossRef
Zurück zum Zitat Linderholm, KR, Skogh, E, Olsson, SK, Dahl, ML, Holtze, M, Engberg, G, Samuelsson, M, Erhardt, S (2010) Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull (Epub ahead of print) Linderholm, KR, Skogh, E, Olsson, SK, Dahl, ML, Holtze, M, Engberg, G, Samuelsson, M, Erhardt, S (2010) Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull (Epub ahead of print)
Zurück zum Zitat Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A (1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17(3):141–150PubMedCrossRef Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A (1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17(3):141–150PubMedCrossRef
Zurück zum Zitat Mansbach RS, Geyer MA (1989) Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2(4):299–308PubMedCrossRef Mansbach RS, Geyer MA (1989) Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2(4):299–308PubMedCrossRef
Zurück zum Zitat Mansbach RS, Geyer MA (1991) Parametric determinants in pre-stimulus modification of acoustic startle: interaction with ketamine. Psychopharmacology (Berl) 105(2):162–168CrossRef Mansbach RS, Geyer MA (1991) Parametric determinants in pre-stimulus modification of acoustic startle: interaction with ketamine. Psychopharmacology (Berl) 105(2):162–168CrossRef
Zurück zum Zitat Marks MJ, Stitzel JA, Collins AC (1985) Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. J Pharmacol Exp Ther 235(3):619–628PubMed Marks MJ, Stitzel JA, Collins AC (1985) Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. J Pharmacol Exp Ther 235(3):619–628PubMed
Zurück zum Zitat Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindstrom LH, Nordin C, Karanti A, Persson P, Erhardt S (2005) Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res 80(2–3):315–322PubMedCrossRef Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindstrom LH, Nordin C, Karanti A, Persson P, Erhardt S (2005) Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res 80(2–3):315–322PubMedCrossRef
Zurück zum Zitat Nilsson LK, Linderholm KR, Erhardt S (2006) Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons. J Neural Transm 113(5):557–571PubMedCrossRef Nilsson LK, Linderholm KR, Erhardt S (2006) Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons. J Neural Transm 113(5):557–571PubMedCrossRef
Zurück zum Zitat Okuno E, Schmidt W, Parks DA, Nakamura M, Schwarcz R (1991) Measurement of rat brain kynurenine aminotransferase at physiological kynurenine concentrations. J Neurochem 57(2):533–540PubMedCrossRef Okuno E, Schmidt W, Parks DA, Nakamura M, Schwarcz R (1991) Measurement of rat brain kynurenine aminotransferase at physiological kynurenine concentrations. J Neurochem 57(2):533–540PubMedCrossRef
Zurück zum Zitat Olsson SK, Andersson AS, Linderholm KR, Holtze M, Nilsson-Todd LK, Schwieler L, Olsson E, Larsson K, Engberg G, Erhardt S (2009) Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. Int J Neuropsychopharmacol 12(4):501–512PubMedCrossRef Olsson SK, Andersson AS, Linderholm KR, Holtze M, Nilsson-Todd LK, Schwieler L, Olsson E, Larsson K, Engberg G, Erhardt S (2009) Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. Int J Neuropsychopharmacol 12(4):501–512PubMedCrossRef
Zurück zum Zitat Parsons CG, Danysz W, Quack G, Hartmann S, Lorenz B, Wollenburg C, Baran L, Przegalinski E, Kostowski W, Krzascik P, Chizh B, Headley PM (1997) Novel systemically active antagonists of the glycine site of the N-methyl-d-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther 283(3):1264–1275PubMed Parsons CG, Danysz W, Quack G, Hartmann S, Lorenz B, Wollenburg C, Baran L, Przegalinski E, Kostowski W, Krzascik P, Chizh B, Headley PM (1997) Novel systemically active antagonists of the glycine site of the N-methyl-d-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther 283(3):1264–1275PubMed
Zurück zum Zitat Potter MC, Elmer GI, Bergeron R, Albuquerque EX, Guidetti P, Wu HQ, Schwarcz R (2010) Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 35(8):1734–1742PubMed Potter MC, Elmer GI, Bergeron R, Albuquerque EX, Guidetti P, Wu HQ, Schwarcz R (2010) Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 35(8):1734–1742PubMed
Zurück zum Zitat Rassoulpour A, Wu HQ, Ferre S, Schwarcz R (2005) Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem 93(3):762–765PubMedCrossRef Rassoulpour A, Wu HQ, Ferre S, Schwarcz R (2005) Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem 93(3):762–765PubMedCrossRef
Zurück zum Zitat Saito K, Quearry BJ, Saito M, Nowak TS Jr, Markey SP, Heyes MP (1993) Kynurenine 3-hydroxylase in brain: species activity differences and effect of gerbil cerebral ischemia. Arch Biochem Biophys 307(1):104–109PubMedCrossRef Saito K, Quearry BJ, Saito M, Nowak TS Jr, Markey SP, Heyes MP (1993) Kynurenine 3-hydroxylase in brain: species activity differences and effect of gerbil cerebral ischemia. Arch Biochem Biophys 307(1):104–109PubMedCrossRef
Zurück zum Zitat Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, Schwarcz R (2006) Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington’s disease. Exp Neurol 197(1):31–40PubMedCrossRef Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, Schwarcz R (2006) Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington’s disease. Exp Neurol 197(1):31–40PubMedCrossRef
Zurück zum Zitat Sathyasaikumar, KV, Stachowski, EK, Wonodi, I, Roberts, RC, Rassoulpour, A, McMahon, RP, Schwarcz, R (2010) Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull (Epub ahead of print) Sathyasaikumar, KV, Stachowski, EK, Wonodi, I, Roberts, RC, Rassoulpour, A, McMahon, RP, Schwarcz, R (2010) Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull (Epub ahead of print)
Zurück zum Zitat Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC (2001) Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50(7):521–530PubMedCrossRef Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC (2001) Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50(7):521–530PubMedCrossRef
Zurück zum Zitat Schwarcz R, Guidetti P, Sathyasaikumar KV, Muchowski PJ (2010) Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington’s disease. Prog Neurobiol 90(2):230–245PubMedCrossRef Schwarcz R, Guidetti P, Sathyasaikumar KV, Muchowski PJ (2010) Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington’s disease. Prog Neurobiol 90(2):230–245PubMedCrossRef
Zurück zum Zitat Schwieler L, Erhardt S, Nilsson L, Linderholm K, Engberg G (2006) Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons–possible involvement of endogenous kynurenic acid. Synapse 59(5):290–298PubMedCrossRef Schwieler L, Erhardt S, Nilsson L, Linderholm K, Engberg G (2006) Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons–possible involvement of endogenous kynurenic acid. Synapse 59(5):290–298PubMedCrossRef
Zurück zum Zitat Schwieler L, Linderholm KR, Nilsson-Todd LK, Erhardt S, Engberg G (2008) Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci 83(5–6):170–175PubMedCrossRef Schwieler L, Linderholm KR, Nilsson-Todd LK, Erhardt S, Engberg G (2008) Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci 83(5–6):170–175PubMedCrossRef
Zurück zum Zitat Shepard PD, Joy B, Clerkin L, Schwarcz R (2003) Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 28(8):1454–1462PubMedCrossRef Shepard PD, Joy B, Clerkin L, Schwarcz R (2003) Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 28(8):1454–1462PubMedCrossRef
Zurück zum Zitat Zhang Y, Colabroy KL, Begley TP, Ealick SE (2005) Structural studies on 3-hydroxyanthranilate-3,4-dioxygenase: the catalytic mechanism of a complex oxidation involved in NAD biosynthesis. Biochemistry 44(21):7632–7643PubMedCrossRef Zhang Y, Colabroy KL, Begley TP, Ealick SE (2005) Structural studies on 3-hydroxyanthranilate-3,4-dioxygenase: the catalytic mechanism of a complex oxidation involved in NAD biosynthesis. Biochemistry 44(21):7632–7643PubMedCrossRef
Metadaten
Titel
Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice
verfasst von
Sara K. Olsson
Markus K. Larsson
Sophie Erhardt
Publikationsdatum
01.02.2012
Verlag
Springer Vienna
Erschienen in
Journal of Neural Transmission / Ausgabe 2/2012
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-011-0706-6

Weitere Artikel der Ausgabe 2/2012

Journal of Neural Transmission 2/2012 Zur Ausgabe

Basic Neurosciences, Genetics and Immunology - Review article

Kynurenines in Parkinson’s disease: therapeutic perspectives

Basic Neurosciences, Genetics and Immunology - Review article

Involvement of kynurenines in Huntington’s disease and stroke-induced brain damage

Basic Neurosciences, Genetics and Immunology - Review article

The kynurenine system and immunoregulation

Basic Neurosciences, Genetics and Immunology - Review article

Kynurenines and headache

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders scheint das auf weibliche Kranke zuzutreffen, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.